S M Tolaney1, J Najita2, J Sperinde3, W Huang4, W Y Chen5, J Savoie6, M Fornier7, E P Winer6, C Bunnell6, I E Krop6. 1. Departments of Medical Oncology. Electronic address: stolaney@partner.org. 2. Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston. 3. Departments of Research and Development. 4. Clinical Research, Monogram Biosciences, Inc., South San Francisco. 5. Departments of Medical Oncology; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston. 6. Departments of Medical Oncology. 7. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: A multicenter NCI-sponsored phase II study was conducted to analyze the safety and efficacy of the combination of ixabepilone with trastuzumab in patients with metastatic HER2-positive breast cancer. PATIENTS AND METHODS: Two cohorts were enrolled: cohort 1 had received no prior chemotherapy or trastuzumab for metastatic disease and cohort 2 had received 1-2 prior trastuzumab-containing regimens for metastatic disease. Patients in both cohorts received ixabepilone 40 mg/m(2) as a 3-h infusion and trastuzumab on day 1 of a 21-day cycle. Tumor biomarkers that may predict response to trastuzumab were explored. RESULTS: Thirty-nine women entered the study with 15 patients in cohort 1 and 24 patients in cohort 2. Across both cohorts, the overall RR was 44%, with a clinical benefit rate (CR + PR + SD for at least 24 weeks) of 56%. Treatment-related toxic effects included neuropathy (grade ≥2, 56%), leukopenia (grade ≥2, 26%), myalgias (grade ≥2, 21%), neutropenia (grade ≥2, 23%), and anemia (grade ≥2, 18%). CONCLUSIONS: This represents the first study of the combination of ixabepilone with trastuzumab for the treatment of metastatic HER2-positive breast cancer. These results suggest that the combination has encouraging activity as first and subsequent line therapy for metastatic breast cancer.
BACKGROUND: A multicenter NCI-sponsored phase II study was conducted to analyze the safety and efficacy of the combination of ixabepilone with trastuzumab in patients with metastatic HER2-positive breast cancer. PATIENTS AND METHODS: Two cohorts were enrolled: cohort 1 had received no prior chemotherapy or trastuzumab for metastatic disease and cohort 2 had received 1-2 prior trastuzumab-containing regimens for metastatic disease. Patients in both cohorts received ixabepilone 40 mg/m(2) as a 3-h infusion and trastuzumab on day 1 of a 21-day cycle. Tumor biomarkers that may predict response to trastuzumab were explored. RESULTS: Thirty-nine women entered the study with 15 patients in cohort 1 and 24 patients in cohort 2. Across both cohorts, the overall RR was 44%, with a clinical benefit rate (CR + PR + SD for at least 24 weeks) of 56%. Treatment-related toxic effects included neuropathy (grade ≥2, 56%), leukopenia (grade ≥2, 26%), myalgias (grade ≥2, 21%), neutropenia (grade ≥2, 23%), and anemia (grade ≥2, 18%). CONCLUSIONS: This represents the first study of the combination of ixabepilone with trastuzumab for the treatment of metastatic HER2-positive breast cancer. These results suggest that the combination has encouraging activity as first and subsequent line therapy for metastatic breast cancer.
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: Allan Lipton; Wolfgang J Köstler; Kim Leitzel; Suhail M Ali; Jeff Sperinde; Jodi Weidler; Agnes Paquet; Thomas Sherwood; Weidong Huang; Michael Bates Journal: Cancer Date: 2010-11-15 Impact factor: 6.860
Authors: P Fumoleau; R Largillier; C Clippe; V Dièras; H Orfeuvre; T Lesimple; S Culine; B Audhuy; D Serin; H Curé; E Vuillemin; J-F Morère; F Montestruc; Z Mouri; M Namer Journal: Eur J Cancer Date: 2004-03 Impact factor: 9.162
Authors: Kim Pedersen; Pier-Davide Angelini; Sirle Laos; Alba Bach-Faig; Matthew P Cunningham; Cristina Ferrer-Ramón; Antonio Luque-García; Jesús García-Castillo; Josep Lluis Parra-Palau; Maurizio Scaltriti; Santiago Ramón y Cajal; José Baselga; Joaquín Arribas Journal: Mol Cell Biol Date: 2009-04-13 Impact factor: 4.272
Authors: Edith A Perez; Guillermo Lerzo; Xavier Pivot; Eva Thomas; Linda Vahdat; Linda Bosserman; Patrice Viens; Can Cai; Brian Mullaney; Ronald Peck; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2007-07-02 Impact factor: 44.544